Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Long-Term Analysis Shows Boston Scientific’s Watchman Device Saves Money

Jul 04 2019

• By Reed Miller

Business man drawing graph of profit compare with cost - Image — • Source: shutterstock.com

Related Content

LAA Closure Devices At The Tipping Point

Sep 29 2015

CLINICAL CORNER: Watchman Appears Cost-Effective, Neuromodulation Data From NANS; BTG’s PneumRx

Dec 16 2015

Related Companies

Boston Scientific Corporation

Abbott

Johnson & Johnson

Additional Topics

Clinical Trials Cost Effectiveness Research & Development Cardiovascular Cardiology Medical Device

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.